Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia

Moving treatment-free remission into mainstream clinical practice in CML

(2016) Timothy P. Hughes et al.   BLOOD

CD57 in human natural killer cells and T-lymphocytes

(2016) Hassen Kared et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

The concept of treatment-free remission in chronic myeloid leukemia

(2016) S Saußele et al.   LEUKEMIA

European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia

(2016) J L Steegmann et al.   LEUKEMIA

Cytomegalovirus Infection Drives Adaptive Epigenetic Diversification of NK Cells with Altered Signaling and Effector Function

(2015) Heinrich Schlums et al.   IMMUNITY

Epigenetic Modification and Antibody-Dependent Expansion of Memory-like NK Cells in Human Cytomegalovirus-Infected Individuals

(2015) Jaewon Lee et al.   IMMUNITY

Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial

(2015) Jun Imagawa et al.   Lancet Haematology

Moving towards patient-centered decision-making in chronic myeloid leukemia: assessment of quality of life and symptom burden

(2014) M. Baccarani et al.   HAEMATOLOGICA

Enlarged Memory T-Cell Pool and Enhanced Th1-Type Responses in Chronic Myeloid Leukemia Patients Who Have Successfully Discontinued IFN-α Monotherapy

(2014) Mette Ilander et al.   PLoS One

NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17)

(2013) R. Romee et al.   BLOOD

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study

(2013) D. M. Ross et al.   BLOOD

A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission

(2012) N. Vey et al.   BLOOD

Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function

(2011) B. Foley et al.   BLOOD

Success Story of Targeted Therapy in Chronic Myeloid Leukemia: A Population-Based Study of Patients Diagnosed in Sweden From 1973 to 2008

(2011) Magnus Björkholm et al.   JOURNAL OF CLINICAL ONCOLOGY

Homeostatic proliferation generates long-lived natural killer cells that respond against viral infection

(2011) Joseph C. Sun et al.   JOURNAL OF EXPERIMENTAL MEDICINE

NK cells are dysfunctional in human chronic myelogenous leukemia before and on imatinib treatment and in BCR–ABL-positive mice

(2011) C I-U Chen et al.   LEUKEMIA

Chronic Myeloid Leukemia Patients in Prolonged Remission following Interferon-α Monotherapy Have Distinct Cytokine and Oligoclonal Lymphocyte Profile

(2011) Anna Kreutzman et al.   PLoS One

Expansion of a unique CD57+NKG2Chi natural killer cell subset during acute human cytomegalovirus infection

(2011) S. Lopez-Verges et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The BCR/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity

(2010) Julia Salih et al.   INTERNATIONAL JOURNAL OF CANCER

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

(2010) François-Xavier Mahon et al.   LANCET ONCOLOGY

Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

(2010) Hagop Kantarjian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia

(2010) Giuseppe Saglio et al.   NEW ENGLAND JOURNAL OF MEDICINE

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

(2009) A Hochhaus et al.   LEUKEMIA

Adaptive immune features of natural killer cells

(2009) Joseph C. Sun et al.   NATURE